TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06906367: A Study of Patients With Fabry Disease (US Specific)

Sponsor: Amicus Therapeutics · Phase: PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 450 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$16,480,000

Rescue Site Savings

+$10,866,500

Unlock Full NCT06906367 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06906367 Rescue Dossier →